Close
RNS Number : 4627C
e-Therapeutics plc
22 January 2018
 

E-THERAPEUTICS PLC

 

("e-Therapeutics" or the "Company")

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES

 

                                                                                     

Oxford, UK, 22 January 2018 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that on 19 January 2018 it granted a total of 2,250,000 options over its ordinary shares of 0.1 pence each to Raymond Barlow, Chief Executive Officer and a Director of the Company, and Steve Medlicott, Finance Director, as follows:

 

Director

Number of options granted

Scheme under which options granted

Exercise price per share

Raymond Barlow

1,500,000

e-Therapeutics Performance Share Plan 2013 (One-Off Awards 2016)

16.76 pence

Steve Medlicott

750,000

e-Therapeutics Performance Share Plan 2013 (Enterprise Management Incentive Share Option Plan)

16.76 pence

 

The options are subject to the achievement of certain performance conditions and, in the event of those conditions being met, the options will vest on the following basis:

·      25% 6 months after the date of this award;

·      50% on the first anniversary of the award;

·      75% 18 months after the date of the award; and

·      100% on the second anniversary of the award.

If the conditions are not satisfied by the second anniversary (and one day) the award will lapse in its entirety.

Following this grant, Raymond Barlow holds a total of 7,000,000 options, and Steve Medlicott holds 2,750,000 options.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Raymond John Barlow

2

Reason for the notification

a)

Position/status 

Chief Executive Officer/Executive Director

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

e-Therapeutics plc 

b)

LEI

21380049RHSSJXWKYT18

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 0.1 pence

 

ISIN:   GB00B2823H99

b)

Nature of the transaction

Grant of options

c)

Price(s) and volume(s)

1,500,000 options over ordinary shares at an exercise price of 16.76 pence per share

 

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

19 January 2018

 

f)

Place of the transaction

LSE, AIM 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Steven Medlicott

2

Reason for the notification

a)

Position/status 

Finance Director/Executive Director

b)

Initial notification/ Amendment 

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

e-Therapeutics plc 

b)

LEI

21380049RHSSJXWKYT18

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code 

Ordinary Shares of 0.1 pence

 

ISIN:   GB00B2823H99

b)

Nature of the transaction

Grant of options 

c)

Price(s) and volume(s)

750,000 options over ordinary shares at an exercise price of 16.76 pence per share

 

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

e)

Date of the transaction

19 January 2018

 

f)

Place of the transaction

LSE, AIM 

 

For further information, please contact:

 

Contacts:

 

e-Therapeutics plc

Ray Barlow, Chief Financial Officer

Steve Medlicott, Finance Director

 

Tel: +44 (0) 1993 883 125

www.etherapeutics.co.uk 

 

Numis Securities Limited

Michael Meade / Freddie Barnfield
(Corporate Finance)

James Black (Corporate Broking)

 

Tel: +44 (0) 207 260 1000

www.numis.com

 

Instinctif Partners

Melanie Toyne Sewell / Deborah Bell

Tel: +44 (0) 207 457 2020

Email: e-therapeutics@instinctif.com

 

 

About e-Therapeutics plc

 

e-Therapeutics is an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.  

Its novel methodology and Discovery Engine allow the Company to discover new and better drugs in a more efficient and effective way.

For more information about the Company, please visit www.etherapeutics.co.uk

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLFFILLDILFIT